作者
Franziska Langhammer,Reza Maroofian,Rueda Badar,Anne Gregor,Michelle Rochman,Jeffrey Ratliff,Marion Koopmans,Theresia Herget,Maja Hempel,Fanny Kortüm,Delphine Héron,Cyril Mignot,Boris Keren,Susan Sklower Brooks,Christina Botti,Bruria Ben‐Zeev,Emanuela Argilli,Elliot H. Sherr,Vykuntaraju K. Gowda,Varunvenkat M. Srinivasan,Somayeh Bakhtiari,Michael C. Kruer,Mustafa A. Salih,Alma Kuechler,Eric Muller,Karli Blocker,Outi Kuismin,Kristen Park,Aaina Kochhar,Kathleen Brown,Subhadra Ramanathan,Robin D. Clark,Magdeldin Elgizouli,Gia Melikishvili,Nazhi Tabatadze,Zornitza Stark,Ghayda Mirzaa,Jinfon Ong,Ute Grasshoff,Andrea Bevot,Lydia von Wintzingerode,Rami Abou Jamra,Yvonne Hennig,Paula Goldenberg,Chadi Al Alam,Majida Charif,Redouane Boulouiz,Mohammed Bellaoui,Rim Amrani,Fuad Al Mutairi,Abdullah Tamim,Firdous Abdulwahab,Fowzan S. Alkuraya,Ebtissal M. Khouj,Javeria Raza Alvi,Tipu Sultan,Narges Hashemi,Ehsan Ghayoor Karimiani,Farah Ashrafzadeh,Shima Imannezhad,Stéphanie Efthymiou,Henry Houlden,Heinrich Sticht,Christiane Zweier
摘要
Purpose Missense variants clustering in the BTB domain region of RHOBTB2 cause a developmental and epileptic encephalopathy with early-onset seizures and severe intellectual disability. Methods By international collaboration, we assembled individuals with pathogenic RHOBTB2 variants and a variable spectrum of neurodevelopmental disorders. By western blotting, we investigated the consequences of missense variants in vitro. Results In accordance with previous observations, de novo heterozygous missense variants in the BTB domain region led to a severe developmental and epileptic encephalopathy in 16 individuals. Now, we also identified de novo missense variants in the GTPase domain in 6 individuals with apparently more variable neurodevelopmental phenotypes with or without epilepsy. In contrast to variants in the BTB domain region, variants in the GTPase domain do not impair proteasomal degradation of RHOBTB2 in vitro, indicating different functional consequences. Furthermore, we observed biallelic splice-site and truncating variants in 9 families with variable neurodevelopmental phenotypes, indicating that complete loss of RHOBTB2 is pathogenic as well. Conclusion By identifying genotype-phenotype correlations regarding location and consequences of de novo missense variants in RHOBTB2 and by identifying biallelic truncating variants, we further delineate and expand the molecular and clinical spectrum of RHOBTB2-related phenotypes, including both autosomal dominant and recessive neurodevelopmental disorders.